INTRODUCTION: Bipolar disorder is a common illness characterized by recurrent episodes of pathological disturbances of mood. The aim of this study was to estimate the annual cost associated with bipolar disorder to the UK healthcare system (National Health Service). METHODS: A retrospective observational study was conducted. Primary care resource use was estimated using the IMS Disease Analyzer, a nationally representative sample of general practitioner (GP) practices. Two sources of data from the NHS Information Centre were used to assess resource use in secondary care and in outpatient and community mental health. The number of bed days and day attendances for patients hospitalized was obtained from the Hospital Episode Statistics (HES). This was supplemented with Mental Health Minimum Dataset (MHMDS) to quantify outpatient and community mental health face-to-face contacts. Resource use was examined between 01 April 2007 and 31 March 2008. RESULTS: The annual NHS cost of bipolar disorder was estimated to be £ 342 million at 2009/2010 prices. Hospitalizations accounted for 60%, outpatient and community mental health 26.7%, and medication in primary care 7.4% of the overall direct costs of care. LIMITATIONS: This study may be confounded by the absence of a control group. This study was limited to an assessment of direct healthcare costs only, not the wider societal cost of bipolar disorder. CONCLUSIONS: The direct medical cost of managing bipolar disorder in the UK healthcare system is considerable. Therapeutic strategies that optimize community-based management, prevention of recurrence and hospitalization could reduce the economic burden of this illness.
INTRODUCTION:Bipolar disorder is a common illness characterized by recurrent episodes of pathological disturbances of mood. The aim of this study was to estimate the annual cost associated with bipolar disorder to the UK healthcare system (National Health Service). METHODS: A retrospective observational study was conducted. Primary care resource use was estimated using the IMS Disease Analyzer, a nationally representative sample of general practitioner (GP) practices. Two sources of data from the NHS Information Centre were used to assess resource use in secondary care and in outpatient and community mental health. The number of bed days and day attendances for patients hospitalized was obtained from the Hospital Episode Statistics (HES). This was supplemented with Mental Health Minimum Dataset (MHMDS) to quantify outpatient and community mental health face-to-face contacts. Resource use was examined between 01 April 2007 and 31 March 2008. RESULTS: The annual NHS cost of bipolar disorder was estimated to be £ 342 million at 2009/2010 prices. Hospitalizations accounted for 60%, outpatient and community mental health 26.7%, and medication in primary care 7.4% of the overall direct costs of care. LIMITATIONS: This study may be confounded by the absence of a control group. This study was limited to an assessment of direct healthcare costs only, not the wider societal cost of bipolar disorder. CONCLUSIONS: The direct medical cost of managing bipolar disorder in the UK healthcare system is considerable. Therapeutic strategies that optimize community-based management, prevention of recurrence and hospitalization could reduce the economic burden of this illness.
Authors: Rebecca Strawbridge; Jessica Fish; Rozmin Halari; John Hodsoll; Clare Reeder; Karine Macritchie; Paul McCrone; Til Wykes; Allan H Young Journal: Trials Date: 2016-07-29 Impact factor: 2.279
Authors: Konstantinos N Fountoulakis; Allan Young; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Pierre Blier; Hans Jurgen Moeller; Siegfried Kasper Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176
Authors: Kim Wright; Alyson Dodd; Fiona C Warren; Antonieta Medina-Lara; Rod Taylor; Steven Jones; Christabel Owens; Mahmood Javaid; Barney Dunn; Julie E Harvey; Alexandra Newbold; Tom Lynch Journal: Trials Date: 2018-10-16 Impact factor: 2.279
Authors: Lumbini Azim; Paul Hindmarch; Georgiana Browne; Thomas Chadwick; Emily Clare; Paul Courtney; Lyndsey Dixon; Nichola Duffelen; Tony Fouweather; John R Geddes; Nicola Goudie; Sandy Harvey; Timea Helter; Eva-Maria Holstein; Garry Martin; Phil Mawson; Jenny McCaffery; Richard Morriss; Judit Simon; Daniel Smith; Paul R A Stokes; Jenn Walker; Chris Weetman; Faye Wolstenhulme; Allan H Young; Stuart Watson; R Hamish McAllister-Williams Journal: BMC Psychiatry Date: 2021-07-05 Impact factor: 3.630